Penobscot Investment Management’s Charles River Laboratories CRL Stock Holding History

Penobscot Investment Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,000	Closed	-$207K	–	315
2024 Q2	$207K	Hold	1,000	–	–	0.02%	299
2024 Q1	$271K	Hold	1,000	–	–	0.03%	265
2023 Q4	$236K	Buy	+1,000	New	+$197K	0.03%	268
2023 Q3	–	Sell	-1,000	Closed	-$210K	–	273
2023 Q2	$210K	Hold	1,000	–	–	0.03%	223
2023 Q1	$202K	Hold	1,000	–	–	0.04%	223
2022 Q4	$218K	Buy	+1,000	New	+$218K	0.04%	216
2022 Q3	–	Sell	-1,000	Closed	-$214K	–	220
2022 Q2	$214K	Hold	1,000	–	–	0.04%	217
2022 Q1	$284K	Hold	1,000	–	–	0.04%	208
2021 Q4	$377K	Hold	1,000	–	–	0.05%	189
2021 Q3	$413K	Hold	1,000	–	–	0.06%	179
2021 Q2	$370K	Hold	1,000	–	–	0.05%	185
2021 Q1	$290K	Hold	1,000	–	–	0.05%	197
2020 Q4	$250K	Hold	1,000	–	–	0.04%	192
2020 Q3	$226K	Buy	+1,000	New	+$208K	0.04%	191

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

Penobscot Investment Management's CRL Position: Q3 2024 in Review

Penobscot Investment Management sold out of Charles River Laboratories (CRL) in Q3 2024, closing a stake of 1,000 shares — an estimated $207K sold.

Penobscot Investment Management first reported a position in CRL in Q3 2020 and held it in 14 quarters. The position peaked at $413K in Q3 2021. 628 funds tracked by Wall St. Rank hold CRL as of Q3 2024.

Penobscot Investment Management reported no remaining Charles River Laboratories position as of Q3 2024 after selling out during the quarter.
Penobscot Investment Management sold 1,000 Charles River Laboratories shares in Q3 2024, an estimated $207K.
Penobscot Investment Management first reported a position in Charles River Laboratories in Q3 2020 and held it in 14 quarters.
Penobscot Investment Management's Charles River Laboratories position peaked at $413K in Q3 2021.
628 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2024.

Based on Penobscot Investment Management's 13F filing for Q3 2024, filed 12 Nov 2024.